Investing.com – United States equities were lower at the close on Thursday, as losses in the Dow Jones Industrials, Dow Jones ...

U.S. stocks were lower after the close on Thursday, as losses in the Industrials, Healthcare and Consumer Goods sectors led ...

Nuvectis Pharma, Inc. (NASDAQ:NVCT) stock is trading lower after the company reported data from the Phase 1b study evaluating ...

Nuvectis Pharma shares fell steeply after updated data from its early-stage study evaluating NXP800 to treat an aggressive type of ovarian cancer showed that a change in the dosing schedule only ...

Nuvectis Pharma (NVCT) stock falls as company posts interim data from a Phase 1b trial for its ovarian cancer drug candidate.

Nuvectis Pharma (NVCT) could be a solid choice for shorter-term investors looking to capitalize on the recent price trend in fundamentally sound stocks. It is one of the many stocks that passed ...

Nuvectis Pharma, Inc. ( (NVCT) ) has released its Q3 earnings. Here is a breakdown of the information Nuvectis Pharma, Inc. presented to its ...

Clinical data update from the NXP800 Phase 1b study expected this month; NXP800 granted Orphan Drug Designation for the treatment of ...

According to the article, Kotak Securities and Citigroup will most likely serve as bankers for the Torrent Pharma transaction. Torrent Pharma shares closed Tuesday’s session at ₹3,207 on the ...

The stock of Nuvectis Pharma Inc (NVCT) has gone up by 1.95% for the week, with a 26.86% rise in the past month and a 20.62% rise in the past quarter. The volatility ratio for the week is 11.38%, and ...

Strides Pharma reported Q2 FY25 net profit of ₹93 Crore, marking a recovery from a ₹131 Crore loss in the same quarter last year. Revenue for Q2 FY25 reached ₹1,201 Crore, reflecting a 20.2% ...